Abivax SA (ABVX) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.139x

Based on the latest financial reports, Abivax SA (ABVX) has a cash flow conversion efficiency ratio of -0.139x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-71.28 Million ≈ $-83.34 Million USD) by net assets (€511.24 Million ≈ $597.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Abivax SA - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Abivax SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Abivax SA for a breakdown of total debt and financial obligations.

Abivax SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Abivax SA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Molina Healthcare Inc NYSE:MOH	-0.073x
Schaeffler India Limited NSE:SCHAEFFLER	0.131x
Zhongtai Securities Co Ltd SHG:600918	-0.252x
Shanghai Pharmaceuticals Holding Co Ltd SHG:601607	0.017x
New Gold Inc TO:NGD	0.227x
Cidara Therapeutics Inc NASDAQ:CDTX	-0.096x
RATIONAL UN.ADR 1/ 1/20 F:RAA1	N/A
HealthEquity Inc NASDAQ:HQY	0.056x

Annual Cash Flow Conversion Efficiency for Abivax SA (2013–2024)

The table below shows the annual cash flow conversion efficiency of Abivax SA from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Abivax SA (ABVX) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€40.58 Million ≈ $47.45 Million	€-154.07 Million ≈ $-180.13 Million	-3.796x	-666.11%
2023-12-31	€196.01 Million ≈ $229.16 Million	€-97.13 Million ≈ $-113.56 Million	-0.496x	+98.58%
2022-12-31	€1.88 Million ≈ $2.20 Million	€-65.58 Million ≈ $-76.67 Million	-34.845x	-2096.03%
2021-12-31	€28.77 Million ≈ $33.64 Million	€-45.66 Million ≈ $-53.38 Million	-1.587x	+75.14%
2020-12-31	€4.67 Million ≈ $5.46 Million	€-29.82 Million ≈ $-34.87 Million	-6.382x	-173.67%
2019-12-31	€11.78 Million ≈ $13.77 Million	€-27.47 Million ≈ $-32.12 Million	-2.332x	-453.39%
2018-12-31	€34.65 Million ≈ $40.51 Million	€-14.60 Million ≈ $-17.07 Million	-0.421x	-140.30%
2017-12-31	€48.18 Million ≈ $56.33 Million	€-8.45 Million ≈ $-9.88 Million	-0.175x	+36.28%
2016-12-31	€56.72 Million ≈ $66.31 Million	€-15.61 Million ≈ $-18.25 Million	-0.275x	-32.46%
2015-12-31	€71.74 Million ≈ $83.87 Million	€-14.90 Million ≈ $-17.42 Million	-0.208x	-113.32%
2014-12-31	€33.94 Million ≈ $39.67 Million	€-3.31 Million ≈ $-3.86 Million	-0.097x	-0.25%
2013-12-31	€34.02 Million ≈ $39.77 Million	€-3.31 Million ≈ $-3.86 Million	-0.097x	--

About Abivax SA

PA:ABVX France Biotechnology

Market Cap

$8.78 Billion

€7.51 Billion EUR

Market Cap Rank

#2866 Global

#55 in France

Share Price

€96.45

Change (1 day)

+3.16%

52-Week Range

€5.06 - €122.40

All Time High

€122.40